Evidence map›Paper›PMID 39633426›Full record

ArticlePneumonia (Nathan Qld.)2024

Pre-vaccination carriage prevalence of Streptococcus pneumoniae serotypes among internally displaced people in Somaliland: a cross-sectional study.

Kevin van Zandvoort, Abdirahman Ibrahim Hassan, Mohamed Omer Bobe, Casey L Pell, Mohamed Saed Ahmed, Belinda D Ortika, Saed Ibrahim, Mohamed Ismail Abdi, Mustapha A Karim, Rosalind M Eggo and 10 more

Registry-linked trialAbstract read
In one paragraph

Article in Pneumonia (Nathan Qld.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04945681 (Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04945681 phase4active not recruitingnot on this map

Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People: A Non-randomised, Quasi-experimental Phase IV Intervention Study

TypeinterventionalSponsorLondon School of Hygiene and Tropical MedicineRan2022 to 2026Enrolled2,882ConditionsPneumococcal InfectionsArmsPneumococcal conjugate vaccine
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kevin van ZandvoortDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. Kevin.Van-Zandvoort@lshtm.ac.uk.
Abdirahman Ibrahim HassanRepublic of Somaliland Ministry of Health Development, Hargeisa, Somaliland.
Mohamed Omer BobeSave the Children International Somaliland, Hargeisa, Somaliland.
Casey L PellInfection, Immunity and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Mohamed Saed AhmedSave the Children International Somaliland, Hargeisa, Somaliland.
Belinda D OrtikaInfection, Immunity and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Saed IbrahimSave the Children International Somaliland, Hargeisa, Somaliland.
Mohamed Ismail AbdiSave the Children International Somaliland, Hargeisa, Somaliland.
Mustapha A KarimRepublic of Somaliland Ministry of Health Development, Hargeisa, Somaliland.
Rosalind M EggoDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Saleban Yousuf AliRepublic of Somaliland Ministry of Health Development, Hargeisa, Somaliland.
Jason HindsInstitute for Infection and Immunity, St. George's, University of London, London, UK.
Saeed Mohamood SolemanRepublic of Somaliland Ministry of Health Development, Hargeisa, Somaliland.
Rachael CummingsSave the Children UK, London, UK.
Catherine R McGowanDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
E Kim MulhollandDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Mohamed Abdi HergeyeRepublic of Somaliland Ministry of Health Development, Hargeisa, Somaliland.
Catherine SatzkeInfection, Immunity and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Francesco ChecchiDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Stefan FlascheDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Funding

National Institute for Health and Care Research NIHR200908Wellcome TrustWellcome Trust 208812/Z/17/Z
6 · The paper itself

Abstract

backgroundPopulations affected by humanitarian crises likely experience high burdens of pneumococcal disease. Streptococcus pneumoniae carriage estimates are essential to understand pneumococcal transmission dynamics and the potential impact of pneumococcal conjugate vaccines (PCV). Over 100 million people are forcibly displaced worldwide, yet here we present only the second pneumococcal carriage estimates for a displaced population.

methodsIn October 2019, we conducted a cross-sectional survey among internally displaced people (IDP) living in Digaale, a permanent IDP camp in Somaliland where PCV has not been implemented. We collected nasopharyngeal swab samples from 453 residents which were assessed for presence of pneumococci and serotyped using DNA microarray.

resultsWe found that pneumococcal carriage prevalence was 36% (95%CI 31-40) in all ages, and 70% (95%CI 64-76) in children under 5. The three most common serotypes were vaccine serotypes 6B, 19F, and 23F. We estimated that the serotypes included in the 10-valent PNEUMOSIL vaccine were carried by 41% (95%CI 33-49) of all pneumococcal carriers and extrapolated that they caused 52% (95%CI 35-70) of invasive pneumococcal disease. We found some evidence that pneumococcal carriage was associated with recent respiratory symptoms, the total number of physical contacts made, and with malnutrition in children under 5. Through linking with a nested contact survey we projected that pneumococcal exposure of children under 2 was predominantly due to contact with children aged 2-5 (39%; 95%CI 31-48) and 6-14 (25%; 95%CI 17-34).

conclusionsThese findings suggest considerable potential for direct and indirect protection against pneumococcal disease in Digaale through PCV use in children and potentially adolescents.

Indexed as

Displaced populationHumanitarian crisisPneumococcal conjugate vaccineSomalilandStreptococcus pneumoniae

Identifiers

PMID39633426
PMCPMC11619265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.